Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Casi Pharmaceuticals doses first patient of CID-103 in Phase 1 myeloma trial » 07:06
06/10/21
06/10
07:06
06/10/21
07:06
CASI

Casi Pharmaceuticals

$1.70 /

+0.06 (+3.66%)

CASI Pharmaceuticals…

CASI Pharmaceuticals announced First-Patient-In in the Phase 1 dose escalation and expansion study of CID-103, an investigational novel anti-CD38 monoclonal antibody, in patients with previously treated, relapsed or refractory multiple myeloma. The study is designed to assess the safety, tolerability, pharmacology and clinical activity of CID-103. CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody that recognizes a unique epitope on CD38. It was engineered to have strong activity against CD38 malignant cells and to reduce certain safety issues observed with existing treatments. Preclinical data of CID-103 demonstrates enhanced activity against a broad array of malignancies which express CD38 and demonstrates a better preclinical safety profile when compared to other CD38 mAbs.

ShowHide Related Items >><<
CASI Casi Pharmaceuticals
$1.70 /

+0.06 (+3.66%)

CASI Casi Pharmaceuticals
$1.70 /

+0.06 (+3.66%)

05/17/21 BTIG
Casi Pharmaceuticals initiated with a Buy at BTIG
05/17/21 BTIG
Casi Pharmaceuticals initiated with a Buy at BTIG
04/26/21 Mizuho
Casi Pharmaceuticals initiated with a Buy at Mizuho
04/26/21 Mizuho
Casi Pharmaceuticals initiated with a Buy at Mizuho
CASI Casi Pharmaceuticals
$1.70 /

+0.06 (+3.66%)

  • 24
    Mar
  • 22
    Jul
CASI Casi Pharmaceuticals
$1.70 /

+0.06 (+3.66%)

Over a week ago
Initiation
Casi Pharmaceuticals initiated with a Buy at BTIG » 16:26
05/17/21
05/17
16:26
05/17/21
16:26
CASI

Casi Pharmaceuticals

$1.43 /

-0.03 (-2.06%)

As previously reported,…

As previously reported, BTIG analyst Justin Zelin initiated coverage of Casi Pharmaceuticals with a Buy rating and $4 price target. Casi is commercial stage and generating revenue from Evomela for use in conditioning regimens prior to stem cell transplant in the treatment of relapsed and refractory multiple myeloma, or r/r MM, while also developing a pipeline of "multiple innovative oncology assets," Zelin tells investors.

ShowHide Related Items >><<
CASI Casi Pharmaceuticals
$1.43 /

-0.03 (-2.06%)

CASI Casi Pharmaceuticals
$1.43 /

-0.03 (-2.06%)

05/17/21 BTIG
Casi Pharmaceuticals initiated with a Buy at BTIG
04/26/21 Mizuho
Casi Pharmaceuticals initiated with a Buy at Mizuho
04/26/21 Mizuho
Casi Pharmaceuticals initiated with a Buy at Mizuho
10/23/20 Oppenheimer
Casi Pharmaceuticals initiated with an Outperform at Oppenheimer
CASI Casi Pharmaceuticals
$1.43 /

-0.03 (-2.06%)

  • 24
    Mar
  • 22
    Jul
CASI Casi Pharmaceuticals
$1.43 /

-0.03 (-2.06%)

Initiation
Casi Pharmaceuticals initiated with a Buy at BTIG » 16:14
05/17/21
05/17
16:14
05/17/21
16:14
CASI

Casi Pharmaceuticals

$1.43 /

-0.025 (-1.72%)

BTIG initiated coverage…

BTIG initiated coverage of Casi Pharmaceuticals with a Buy rating and $4 price target.

ShowHide Related Items >><<
CASI Casi Pharmaceuticals
$1.43 /

-0.025 (-1.72%)

CASI Casi Pharmaceuticals
$1.43 /

-0.025 (-1.72%)

04/26/21 Mizuho
Casi Pharmaceuticals initiated with a Buy at Mizuho
04/26/21 Mizuho
Casi Pharmaceuticals initiated with a Buy at Mizuho
10/23/20 Oppenheimer
Casi Pharmaceuticals initiated with an Outperform at Oppenheimer
CASI Casi Pharmaceuticals
$1.43 /

-0.025 (-1.72%)

  • 24
    Mar
  • 22
    Jul
CASI Casi Pharmaceuticals
$1.43 /

-0.025 (-1.72%)

Over a month ago
Earnings
Casi Pharmaceuticals reports Q1 EPS (11c), consensus (6c) » 07:02
05/13/21
05/13
07:02
05/13/21
07:02
CASI

Casi Pharmaceuticals

$1.46 /

+0.01 (+0.69%)

Reports Q1 revenue $5.7M,…

Reports Q1 revenue $5.7M, consensus $5.05M. CEO Wei-Wu He commented, "We are pleased to report $5.7M Evomela revenues for the quarter. For the full year 2021, we expect to meet our guidance of greater than 50% revenue growth. In addition to upward trend in Evomela revenue, our Q1 was marked by our new China partnership with Cleave Therapeutics for CB-5339, an exciting first-in-class VCP/p97 inhibitor being investigated for hematological malignancies and solid tumors. We also completed a $32.5M capital raise at the end of March, from new fundamentally-driven, healthcare-dedicated investors, to strengthen our balance sheet. I am thrilled with the progress we are seeing across our hematology oncology product portfolio. With respect to our commercial asset CNCT-19, our partner Juventas is making excellent progress with their current registration trials in B-NHL and B-ALL and is expecting to file NDAs in China by the end of 2021. Our CID-103 anti-CD38 monoclonal antibody Phase I trial remains on track with first patient dosing expected later this month, BI-1206 anti-FcyRIIB monoclonal antibody is on track with our China IND submission expected this year. We are excited by our momentum and will continue to execute on a number of key milestones across our broad portfolio in the quarters ahead."

ShowHide Related Items >><<
CASI Casi Pharmaceuticals
$1.46 /

+0.01 (+0.69%)

CASI Casi Pharmaceuticals
$1.46 /

+0.01 (+0.69%)

04/26/21 Mizuho
Casi Pharmaceuticals initiated with a Buy at Mizuho
04/26/21 Mizuho
Casi Pharmaceuticals initiated with a Buy at Mizuho
10/23/20 Oppenheimer
Casi Pharmaceuticals initiated with an Outperform at Oppenheimer
  • 24
    Mar
  • 22
    Jul
CASI Casi Pharmaceuticals
$1.46 /

+0.01 (+0.69%)

Initiation
Casi Pharmaceuticals initiated with a Buy at Mizuho » 06:43
04/26/21
04/26
06:43
04/26/21
06:43
CASI

Casi Pharmaceuticals

$1.66 /

+0.02 (+1.22%)

Mizuho analyst Difei Yang…

Mizuho analyst Difei Yang initiated coverage of Casi Pharmaceuticals with a Buy rating and $3.80 price target. The company is well positioned to benefit from the "sizable and rapidly-growing" China healthcare/biotech market, Yang tells investors in a research note. Casi's first commercial launch, a conditioning regimen agent for multiple myeloma, has been successful thus far, says the analyst, who is bullish on its lead pipeline asset, a CD19 CAR-T for liquid tumors.

ShowHide Related Items >><<
CASI Casi Pharmaceuticals
$1.66 /

+0.02 (+1.22%)

CASI Casi Pharmaceuticals
$1.66 /

+0.02 (+1.22%)

10/23/20 Oppenheimer
Casi Pharmaceuticals initiated with an Outperform at Oppenheimer
CASI Casi Pharmaceuticals
$1.66 /

+0.02 (+1.22%)

  • 24
    Mar
  • 22
    Jul
CASI Casi Pharmaceuticals
$1.66 /

+0.02 (+1.22%)

Initiation
Casi Pharmaceuticals initiated with a Buy at Mizuho » 06:43
04/26/21
04/26
06:43
04/26/21
06:43
CASI

Casi Pharmaceuticals

$1.66 /

+0.02 (+1.22%)

Mizuho analyst Difei Yang…

Mizuho analyst Difei Yang initiated coverage of Casi Pharmaceuticals with a Buy rating and $3.80 price target. The company is well positioned to benefit from the "sizable and rapidly-growing" China healthcare/biotech market, Yang tells investors in a research note. Casi's first commercial launch, a conditioning regimen agent for multiple myeloma, has been successful thus far, says the analyst, who is bullish on its lead pipeline asset, a CD19 CAR-T for liquid tumors.

ShowHide Related Items >><<
CASI Casi Pharmaceuticals
$1.66 /

+0.02 (+1.22%)

CASI Casi Pharmaceuticals
$1.66 /

+0.02 (+1.22%)

10/23/20 Oppenheimer
Casi Pharmaceuticals initiated with an Outperform at Oppenheimer
CASI Casi Pharmaceuticals
$1.66 /

+0.02 (+1.22%)

  • 24
    Mar
  • 22
    Jul
CASI Casi Pharmaceuticals
$1.66 /

+0.02 (+1.22%)

On The Fly
Fly Intel: Pre-market Movers » 08:54
03/31/21
03/31
08:54
03/31/21
08:54
LCTX

Lineage Cell Therapeutics

$2.25 /

+0.105 (+4.90%)

, CASI

Casi Pharmaceuticals

$1.98 /

-0.01 (-0.50%)

, EQ

Equillium

$6.63 /

+0.05 (+0.76%)

, WBA

Walgreens Boots Alliance

$53.12 /

+0.26 (+0.49%)

, CHWY

Chewy

$80.39 /

+1.6 (+2.03%)

, LULU

Lululemon

$317.46 /

+1.37 (+0.43%)

, RMO

Romeo Power

$10.35 /

-0.53 (-4.87%)

, BB

BlackBerry

$9.34 /

+0.13 (+1.41%)

, PRQR

ProQR Therapeutics

$7.13 /

-0.69 (-8.82%)

Check out this morning's…

ShowHide Related Items >><<
WBA Walgreens Boots Alliance
$53.12 /

+0.26 (+0.49%)

RMO Romeo Power
$10.35 /

-0.53 (-4.87%)

PRQR ProQR Therapeutics
$7.13 /

-0.69 (-8.82%)

LULU Lululemon
$317.46 /

+1.37 (+0.43%)

LCTX Lineage Cell Therapeutics
$2.25 /

+0.105 (+4.90%)

EQ Equillium
$6.63 /

+0.05 (+0.76%)

CHWY Chewy
$80.39 /

+1.6 (+2.03%)

CASI Casi Pharmaceuticals
$1.98 /

-0.01 (-0.50%)

BB BlackBerry
$9.34 /

+0.13 (+1.41%)

LCTX Lineage Cell Therapeutics
$2.25 /

+0.105 (+4.90%)

03/30/21 Cantor Fitzgerald
Lineage Cell Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/17/20 Noble Capital
Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
08/31/20 H.C. Wainwright
Lineage Cell extends cash runway to over two years, says H.C. Wainwright
06/09/20 H.C. Wainwright
Lineage Cell Therapeutics price target raised to $7 from $4 at H.C. Wainwright
CASI Casi Pharmaceuticals
$1.98 /

-0.01 (-0.50%)

10/23/20 Oppenheimer
Casi Pharmaceuticals initiated with an Outperform at Oppenheimer
EQ Equillium
$6.63 /

+0.05 (+0.76%)

03/03/21
Fly Intel: Top five analyst initiations
03/03/21 JonesTrading
Equillium initiated with a Buy at JonesTrading
11/30/20 H.C. Wainwright
Equillium price target lowered to $12 from $22 at H.C. Wainwright
07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
WBA Walgreens Boots Alliance
$53.12 /

+0.26 (+0.49%)

03/29/21 Cowen
Walgreens Boots Alliance price target raised to $53 from $41 at Cowen
03/25/21 Deutsche Bank
Deutsche names Walgreens short-term buy idea, boosts price target
03/16/21 Morgan Stanley
Higher vaccine reimbursement a 'windfall' for pharmacies, says Morgan Stanley
01/27/21 Deutsche Bank
Walgreens Boots Alliance price target raised to $49 from $44 at Deutsche Bank
CHWY Chewy
$80.39 /

+1.6 (+2.03%)

03/31/21 Wedbush
Chewy price target raised to $100 from $90 at Wedbush
03/31/21 Jefferies
Chewy price target raised to $105 from $100 at Jefferies
03/31/21 Morgan Stanley
Chewy price target raised to $83 from $76 at Morgan Stanley
03/25/21 Cleveland Research
Chewy Q4 net sales estimate raised after checks at Cleveland Research
LULU Lululemon
$317.46 /

+1.37 (+0.43%)

03/31/21 B. Riley
Lululemon price target lowered to $374 from $409 at B. Riley Securities
03/31/21 Cowen
Lululemon consensus estimates need to be lowered, says Cowen
03/31/21 Baird
Lululemon price target lowered to $395 from $425 at Baird
03/31/21 RBC Capital
Lululemon price target lowered to $380 from $435 at RBC Capital
RMO Romeo Power
$10.35 /

-0.53 (-4.87%)

03/31/21 Williams Capital
Romeo Power downgraded to Hold from Buy at Williams Trading
03/08/21 Cowen
Cowen bullish on battery technology, starts Romeo Power at Outperform
03/08/21 Cowen
Romeo Power initiated with an Outperform at Cowen
02/11/21 Morgan Stanley
Romeo Power initiated with an Underweight at Morgan Stanley
BB BlackBerry
$9.34 /

+0.13 (+1.41%)

03/31/21 Canaccord
BlackBerry upgraded to Hold from Sell at Canaccord
02/16/21
Fly Intel: Top five analyst downgrades
02/16/21 Canaccord
BlackBerry cut to Sell after 'targeted short squeeze' at Canaccord
02/16/21 Canaccord
BlackBerry downgraded to Sell from Hold at Canaccord
PRQR ProQR Therapeutics
$7.13 /

-0.69 (-8.82%)

03/25/21 Citi
ProQR Therapeutics price target raised to $44 from $33 at Citi
03/24/21 Cantor Fitzgerald
ProQR Therapeutics price target raised to $33 from $22 at Cantor Fitzgerald
03/24/21 JMP Securities
ProQR Therapeutics price target raised to $35 from $19 at JMP Securities
11/02/20 Cantor Fitzgerald
ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald
WBA Walgreens Boots Alliance
$53.12 /

+0.26 (+0.49%)

RMO Romeo Power
$10.35 /

-0.53 (-4.87%)

PRQR ProQR Therapeutics
$7.13 /

-0.69 (-8.82%)

LULU Lululemon
$317.46 /

+1.37 (+0.43%)

LCTX Lineage Cell Therapeutics
$2.25 /

+0.105 (+4.90%)

EQ Equillium
$6.63 /

+0.05 (+0.76%)

CHWY Chewy
$80.39 /

+1.6 (+2.03%)

CASI Casi Pharmaceuticals
$1.98 /

-0.01 (-0.50%)

BB BlackBerry
$9.34 /

+0.13 (+1.41%)

  • 31
    Mar
  • 24
    Mar
  • 17
    Sep
  • 14
    Aug
  • 22
    Jul
WBA Walgreens Boots Alliance
$53.12 /

+0.26 (+0.49%)

LULU Lululemon
$317.46 /

+1.37 (+0.43%)

CHWY Chewy
$80.39 /

+1.6 (+2.03%)

BB BlackBerry
$9.34 /

+0.13 (+1.41%)

WBA Walgreens Boots Alliance
$53.12 /

+0.26 (+0.49%)

RMO Romeo Power
$10.35 /

-0.53 (-4.87%)

LULU Lululemon
$317.46 /

+1.37 (+0.43%)

EQ Equillium
$6.63 /

+0.05 (+0.76%)

CHWY Chewy
$80.39 /

+1.6 (+2.03%)

CASI Casi Pharmaceuticals
$1.98 /

-0.01 (-0.50%)

BB BlackBerry
$9.34 /

+0.13 (+1.41%)

WBA Walgreens Boots Alliance
$53.12 /

+0.26 (+0.49%)

RMO Romeo Power
$10.35 /

-0.53 (-4.87%)

LULU Lululemon
$317.46 /

+1.37 (+0.43%)

EQ Equillium
$6.63 /

+0.05 (+0.76%)

CHWY Chewy
$80.39 /

+1.6 (+2.03%)

BB BlackBerry
$9.34 /

+0.13 (+1.41%)

On The Fly
Fly Intel: After-Hours Movers » 19:05
03/30/21
03/30
19:05
03/30/21
19:05
RMO

Romeo Power

$10.35 /

-0.53 (-4.87%)

, MILE

Metromile

$11.22 /

-0.21 (-1.84%)

, CRNX

Crinetics

$15.45 /

-0.2 (-1.28%)

, BB

BlackBerry

$9.34 /

+0.13 (+1.41%)

, EDAP

EDAP TMS

$9.55 /

-0.13 (-1.34%)

, BEEM

Beam Global

$37.15 /

+1.85 (+5.24%)

, APR

Apria

$25.61 /

+0.63 (+2.52%)

, CAAP

Corporacion America Airport

$4.95 /

+0.24 (+5.10%)

, LULU

Lululemon

$317.46 /

+1.37 (+0.43%)

, NMTR

9 Meters Biopharma

$1.37 /

+0.035 (+2.63%)

, CHWY

Chewy

$80.39 /

+1.6 (+2.03%)

, HYFM

Hydrofarm

$53.10 /

+1.16 (+2.23%)

, PHR

Phreesia

$52.25 /

+1.46 (+2.87%)

, PVH

PVH Corp.

$100.25 /

+2.26 (+2.31%)

, PRPH

ProPhase Labs

$6.29 /

+0.06 (+0.96%)

, SURF

Surface Oncology

$7.25 /

-0.7 (-8.81%)

, CASI

Casi Pharmaceuticals

$1.98 /

-0.01 (-0.50%)

, CLF

Cleveland-Cliffs

$17.25 /

+1.01 (+6.22%)

, SLCA

U.S. Silica

$11.88 /

+0.195 (+1.67%)

, AVO

Mission Produce

$18.05 /

-0.3801 (-2.06%)

Check out this evening's…

ShowHide Related Items >><<
SURF Surface Oncology
$7.25 /

-0.7 (-8.81%)

SLCA U.S. Silica
$11.88 /

+0.195 (+1.67%)

RMO Romeo Power
$10.35 /

-0.53 (-4.87%)

PVH PVH Corp.
$100.25 /

+2.26 (+2.31%)

PRPH ProPhase Labs
$6.29 /

+0.06 (+0.96%)

PHR Phreesia
$52.25 /

+1.46 (+2.87%)

NMTR 9 Meters Biopharma
$1.37 /

+0.035 (+2.63%)

MILE Metromile
$11.22 /

-0.21 (-1.84%)

LULU Lululemon
$317.46 /

+1.37 (+0.43%)

HYFM Hydrofarm
$53.10 /

+1.16 (+2.23%)

EDAP EDAP TMS
$9.55 /

-0.13 (-1.34%)

CRNX Crinetics
$15.45 /

-0.2 (-1.28%)

CLF Cleveland-Cliffs
$17.25 /

+1.01 (+6.22%)

CHWY Chewy
$80.39 /

+1.6 (+2.03%)

CASI Casi Pharmaceuticals
$1.98 /

-0.01 (-0.50%)

CAAP Corporacion America Airport
$4.95 /

+0.24 (+5.10%)

BEEM Beam Global
$37.15 /

+1.85 (+5.24%)

BB BlackBerry
$9.34 /

+0.13 (+1.41%)

AVO Mission Produce
$18.05 /

-0.3801 (-2.06%)

APR Apria
$25.61 /

+0.63 (+2.52%)

RMO Romeo Power
$10.35 /

-0.53 (-4.87%)

03/08/21 Cowen
Cowen bullish on battery technology, starts Romeo Power at Outperform
03/08/21 Cowen
Romeo Power initiated with an Outperform at Cowen
02/11/21 Morgan Stanley
Romeo Power initiated with an Underweight at Morgan Stanley
MILE Metromile
$11.22 /

-0.21 (-1.84%)

CRNX Crinetics
$15.45 /

-0.2 (-1.28%)

11/24/20 Piper Sandler
Crinetics could take 'sizable share' in $3.1B market, says Piper Sandler
11/23/20 Cantor Fitzgerald
Crinetics price target raised to $42 from $38 at Cantor Fitzgerald
10/26/20 Piper Sandler
ACROBAT data improve odds of Phase 3 success for Crinetics, says Piper Sandler
10/14/20 JPMorgan
Crinetics resumed with a Neutral at JPMorgan
BB BlackBerry
$9.34 /

+0.13 (+1.41%)

02/16/21
Fly Intel: Top five analyst downgrades
02/16/21 Canaccord
BlackBerry cut to Sell after 'targeted short squeeze' at Canaccord
02/16/21 Canaccord
BlackBerry downgraded to Sell from Hold at Canaccord
01/27/21 Scotiabank
Scotiabank downgrades BlackBerry to Underperform after 'overdone' rally
EDAP EDAP TMS
$9.55 /

-0.13 (-1.34%)

01/25/21 Lake Street
EDAP TMS initiated with a Buy at Lake Street
01/22/21 B. Riley
EDAP TMS price target raised to $13 from $11.50 at B. Riley Securities
01/12/21 B. Riley
EDAP TMS price target raised to $11.50 from $5.50 at B. Riley Securities
04/15/20
Fly Intel: Top five analyst initiations
BEEM Beam Global
$37.15 /

+1.85 (+5.24%)

03/08/21 Cowen
Beam Global initiated with a Market Perform at Cowen
02/05/21 Roth Capital
Beam Global initiated with a Buy at Roth Capital
12/29/20 Maxim
Maxim boosts Beam Global price target to $90 on EV charging products
12/29/20 Maxim
Beam Global price target raised to $90 from $45 at Maxim
APR Apria
$25.61 /

+0.63 (+2.52%)

03/24/21 Citi
CMS oxygen rate change may drive upside for Apria, says Citi
03/08/21 Citi
Apria initiated with a Buy at Citi
03/08/21 Goldman Sachs
Apria initiated with a Buy at Goldman Sachs
03/08/21 Piper Sandler
Apria initiated with an Overweight at Piper Sandler
CAAP Corporacion America Airport
$4.95 /

+0.24 (+5.10%)

04/08/20 Goldman Sachs
Corporacion America Airport downgraded to Neutral from Buy at Goldman Sachs
LULU Lululemon
$317.46 /

+1.37 (+0.43%)

03/29/21 Piper Sandler
Lululemon selloff brings 'compelling entry point,' says Piper Sandler
03/17/21 Morgan Stanley
Lululemon price target lowered to $386 from $400 at Morgan Stanley
03/15/21 Cowen
Lululemon price target lowered to $389 from $409 at Cowen
01/13/21 Morgan Stanley
Lululemon price target raised to $400 from $381 at Morgan Stanley
NMTR 9 Meters Biopharma
$1.37 /

+0.035 (+2.63%)

03/25/21 Brookline
9 Meters Biopharma assumed with a Buy at Brookline
01/28/21 Oppenheimer
9 Meters Biopharma initiated with an Outperform at Oppenheimer
10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Maxim
9 Meters Biopharma initiated with a Buy at Maxim
CHWY Chewy
$80.39 /

+1.6 (+2.03%)

03/25/21 Cleveland Research
Chewy Q4 net sales estimate raised after checks at Cleveland Research
03/25/21 JPMorgan
JPMorgan positive on Chewy fundamentals into Q4 report
03/09/21 Citi
Citi starts Best Buy with Sell, sees 'too many red flags'
03/08/21 Citi
Chewy initiated with a Neutral at Citi
HYFM Hydrofarm
$53.10 /

+1.16 (+2.23%)

02/22/21 Truist
Hydrofarm price target raised to $95 from $65 at Truist
01/04/21 William Blair
Hydrofarm initiated with an Outperform at William Blair
01/04/21 Truist
Hydrofarm initiated with a Buy at Truist
01/04/21 Deutsche Bank
Hydrofarm initiated with a Buy at Deutsche Bank
PHR Phreesia
$52.25 /

+1.46 (+2.87%)

01/14/21 Needham
Phreesia price target raised to $70 from $60 at Needham
01/08/21 Baird
Vocera downgraded to Neutral on valuation at Baird
01/04/21 Stephens
Brinker, LiveRamp and Vonage among 2021 best ideas at Stephens
12/14/20 Citi
Phreesia price target raised to $59 from $33 at Citi
PVH PVH Corp.
$100.25 /

+2.26 (+2.31%)

03/29/21 Piper Sandler
PVH Corp. price target raised to $109 from $93 at Piper Sandler
01/27/21 Citi
PVH Corp. price target raised to $105 from $92 at Citi
01/21/21 Deutsche Bank
PVH Corp. price target raised to $112 from $87 at Deutsche Bank
01/07/21 JPMorgan
PVH Corp. price target raised to $101 from $88 at JPMorgan
PRPH ProPhase Labs
$6.29 /

+0.06 (+0.96%)

01/20/21 Dawson James
ProPhase Labs initiated with a Buy at Dawson James
SURF Surface Oncology
$7.25 /

-0.7 (-8.81%)

03/10/21 Wedbush
Surface Oncology risk/reward 'highly favorable' into data, says Wedbush
12/18/20 H.C. Wainwright
Surface Oncology price target raised to $15 from $11 at H.C. Wainwright
09/04/20
Fly Intel: Top five analyst initiations
09/04/20 H.C. Wainwright
Surface Oncology initiated with a Buy at H.C. Wainwright
CASI Casi Pharmaceuticals
$1.98 /

-0.01 (-0.50%)

10/23/20 Oppenheimer
Casi Pharmaceuticals initiated with an Outperform at Oppenheimer
CLF Cleveland-Cliffs
$17.25 /

+1.01 (+6.22%)

02/03/21 Credit Suisse
U.S. Steel Industry upgraded to Overweight at Credit Suisse
01/26/21 GLJ Research
Cleveland-Cliffs downgraded to Hold on 'emerging headwinds' at GLJ Research
01/26/21 GLJ Research
Cleveland-Cliffs downgraded to Hold from Buy at GLJ Research
01/18/21 Exane BNP Paribas
Cleveland-Cliffs upgraded to Outperform from Neutral at Exane BNP Paribas
SLCA U.S. Silica
$11.88 /

+0.195 (+1.67%)

03/02/21 B. Riley
U.S. Silica price target raised to $15 from $4.35 at B. Riley Securities
01/04/21 Evercore ISI
U.S. Silica upgraded to Outperform from In Line at Evercore ISI
12/15/20 Citi
U.S. Silica upgraded to Neutral from Sell at Citi
07/22/20 B. Riley
U.S. Silica price target raised to $4.35 from $3 at B. Riley FBR
AVO Mission Produce
$18.05 /

-0.3801 (-2.06%)

03/23/21 Citi
Mission Produce downgraded to Neutral from Buy at Citi
03/15/21 DA Davidson
Mission Produce price target raised to $27 from $18 at DA Davidson
03/11/21
Fly Intel: Top five analyst downgrades
03/11/21 JPMorgan
Mission Produce downgraded to Neutral on valuation at JPMorgan
SURF Surface Oncology
$7.25 /

-0.7 (-8.81%)

SLCA U.S. Silica
$11.88 /

+0.195 (+1.67%)

RMO Romeo Power
$10.35 /

-0.53 (-4.87%)

PVH PVH Corp.
$100.25 /

+2.26 (+2.31%)

PHR Phreesia
$52.25 /

+1.46 (+2.87%)

NMTR 9 Meters Biopharma
$1.37 /

+0.035 (+2.63%)

MILE Metromile
$11.22 /

-0.21 (-1.84%)

LULU Lululemon
$317.46 /

+1.37 (+0.43%)

HYFM Hydrofarm
$53.10 /

+1.16 (+2.23%)

EDAP EDAP TMS
$9.55 /

-0.13 (-1.34%)

CRNX Crinetics
$15.45 /

-0.2 (-1.28%)

CLF Cleveland-Cliffs
$17.25 /

+1.01 (+6.22%)

CHWY Chewy
$80.39 /

+1.6 (+2.03%)

CASI Casi Pharmaceuticals
$1.98 /

-0.01 (-0.50%)

CAAP Corporacion America Airport
$4.95 /

+0.24 (+5.10%)

BEEM Beam Global
$37.15 /

+1.85 (+5.24%)

BB BlackBerry
$9.34 /

+0.13 (+1.41%)

AVO Mission Produce
$18.05 /

-0.3801 (-2.06%)

APR Apria
$25.61 /

+0.63 (+2.52%)

  • 31
    Mar
  • 24
    Mar
  • 09
    Feb
  • 11
    Feb
  • 11
    Dec
  • 10
    Dec
  • 21
    Oct
  • 01
    Oct
  • 17
    Sep
  • 22
    Jul
  • 15
    Apr
LULU Lululemon
$317.46 /

+1.37 (+0.43%)

CHWY Chewy
$80.39 /

+1.6 (+2.03%)

BB BlackBerry
$9.34 /

+0.13 (+1.41%)

SURF Surface Oncology
$7.25 /

-0.7 (-8.81%)

RMO Romeo Power
$10.35 /

-0.53 (-4.87%)

PVH PVH Corp.
$100.25 /

+2.26 (+2.31%)

PRPH ProPhase Labs
$6.29 /

+0.06 (+0.96%)

PHR Phreesia
$52.25 /

+1.46 (+2.87%)

NMTR 9 Meters Biopharma
$1.37 /

+0.035 (+2.63%)

LULU Lululemon
$317.46 /

+1.37 (+0.43%)

HYFM Hydrofarm
$53.10 /

+1.16 (+2.23%)

CLF Cleveland-Cliffs
$17.25 /

+1.01 (+6.22%)

CHWY Chewy
$80.39 /

+1.6 (+2.03%)

CASI Casi Pharmaceuticals
$1.98 /

-0.01 (-0.50%)

BEEM Beam Global
$37.15 /

+1.85 (+5.24%)

BB BlackBerry
$9.34 /

+0.13 (+1.41%)

AVO Mission Produce
$18.05 /

-0.3801 (-2.06%)

APR Apria
$25.61 /

+0.63 (+2.52%)

RMO Romeo Power
$10.35 /

-0.53 (-4.87%)

PVH PVH Corp.
$100.25 /

+2.26 (+2.31%)

PRPH ProPhase Labs
$6.29 /

+0.06 (+0.96%)

PHR Phreesia
$52.25 /

+1.46 (+2.87%)

NMTR 9 Meters Biopharma
$1.37 /

+0.035 (+2.63%)

MILE Metromile
$11.22 /

-0.21 (-1.84%)

LULU Lululemon
$317.46 /

+1.37 (+0.43%)

HYFM Hydrofarm
$53.10 /

+1.16 (+2.23%)

CLF Cleveland-Cliffs
$17.25 /

+1.01 (+6.22%)

CHWY Chewy
$80.39 /

+1.6 (+2.03%)

CAAP Corporacion America Airport
$4.95 /

+0.24 (+5.10%)

BEEM Beam Global
$37.15 /

+1.85 (+5.24%)

BB BlackBerry
$9.34 /

+0.13 (+1.41%)

Hot Stocks
Casi Pharmaceuticals CEO buys 3M share of common stock » 17:21
03/30/21
03/30
17:21
03/30/21
17:21
CASI

Casi Pharmaceuticals

$1.98 /

-0.01 (-0.50%)

In a regulatory filing,…

In a regulatory filing, Casi Pharmaceuticals disclosed that its CEO Wei-Wu He bought 3M shares of common stock on March 26th in a total transaction size of $6.15M, increasing his stake by about 24%. Shares of Casi are up about 8% afterhours at $2.15.

ShowHide Related Items >><<
CASI Casi Pharmaceuticals
$1.98 /

-0.01 (-0.50%)

CASI Casi Pharmaceuticals
$1.98 /

-0.01 (-0.50%)

10/23/20 Oppenheimer
Casi Pharmaceuticals initiated with an Outperform at Oppenheimer
CASI Casi Pharmaceuticals
$1.98 /

-0.01 (-0.50%)

  • 24
    Mar
  • 22
    Jul
CASI Casi Pharmaceuticals
$1.98 /

-0.01 (-0.50%)

On The Fly
Fly Intel: Pre-market Movers » 08:56
03/24/21
03/24
08:56
03/24/21
08:56
INTC

Intel

$63.47 /

-2.19 (-3.34%)

, TSLA

Tesla

$662.17 /

-7.83 (-1.17%)

, HOFV

Hall of Fame Resort & Entertainment

$4.04 /

-1.22 (-23.19%)

, DLPN

Dolphin Entertainment

$18.20 /

+12.78 (+235.79%)

, AGRX

Agile Therapeutics

$1.89 /

-0.13 (-6.45%)

, IPHI

Inphi

$161.66 /

-3.58 (-2.17%)

, GIS

General Mills

$61.21 /

-0.29 (-0.47%)

, GME

GameStop

$181.00 /

-13.41 (-6.90%)

, EYES

Second Sight

$11.00 /

-1.65 (-13.04%)

, MP

MP Materials

$37.04 /

-8.165 (-18.06%)

, CASI

Casi Pharmaceuticals

$2.28 /

-0.11 (-4.60%)

, BTC

Bitcoin

$0.00 /

+ (+0.00%)

, BITCOIN

Bitcoin

$0.00 /

+ (+0.00%)

, MRVL

Marvell

$46.12 /

-1.56 (-3.27%)

Check out this morning's…

ShowHide Related Items >><<
TSLA Tesla
$662.17 /

-7.83 (-1.17%)

MRVL Marvell
$46.12 /

-1.56 (-3.27%)

MP MP Materials
$37.04 /

-8.165 (-18.06%)

IPHI Inphi
$161.66 /

-3.58 (-2.17%)

INTC Intel
$63.47 /

-2.19 (-3.34%)

HOFV Hall of Fame Resort & Entertainment
$4.04 /

-1.22 (-23.19%)

GME GameStop
$181.00 /

-13.41 (-6.90%)

GIS General Mills
$61.21 /

-0.29 (-0.47%)

EYES Second Sight
$11.00 /

-1.65 (-13.04%)

DLPN Dolphin Entertainment
$18.20 /

+12.78 (+235.79%)

CASI Casi Pharmaceuticals
$2.28 /

-0.11 (-4.60%)

BTC Bitcoin
$0.00 /

+ (+0.00%)

BITCOIN Bitcoin
$0.00 /

+ (+0.00%)

AGRX Agile Therapeutics
$1.89 /

-0.13 (-6.45%)

INTC Intel
$63.47 /

-2.19 (-3.34%)

03/24/21 Northland
Intel foundry initiative 'has a low probability of success,' says Northland
03/24/21 Rosenblatt
Intel adding new dimension of execution risk in foundry battle, says Rosenblatt
03/24/21 Evercore ISI
Intel price target raised to $75 from $68 at Evercore ISI
03/24/21 Needham
Intel price target raised to $74 from $70 at Needham
TSLA Tesla
$662.17 /

-7.83 (-1.17%)

03/24/21 Piper Sandler
Tesla selloffs on truck production delays likely, says Piper Sandler
03/24/21 Wedbush
Wedbush sees bitcoin accepted to buy a Tesla as 'major step' in crypto world
03/22/21 Deutsche Bank
Deutsche Bank raises Volkswagen price target to EUR 270, says 'all-in' on BEVs
03/22/21 Wedbush
Tesla puts strategic 'line in the sand' with China amid tensions, says Wedbush
HOFV Hall of Fame Resort & Entertainment
$4.04 /

-1.22 (-23.19%)

12/15/20 Maxim
Hall of Fame Resort & Entertainment initiated with a Buy at Maxim
DLPN Dolphin Entertainment
$18.20 /

+12.78 (+235.79%)

AGRX Agile Therapeutics
$1.89 /

-0.13 (-6.45%)

12/08/20 H.C. Wainwright
Agile Therapeutics price target raised to $7 from $6 at H.C. Wainwright
09/22/20 H.C. Wainwright
H.C. Wainwright says Agile coverage, access for Twirla launch underappreciated
IPHI Inphi
$161.66 /

-3.58 (-2.17%)

03/24/21 Stifel
Chinese approval for Inphi deal 'highly favorable' for Marvell, says Stifel
02/16/21 Needham
Inphi price target raised to $191 from $175 at Needham
02/09/21 Barclays
Inphi downgraded to Equal Weight on Marvell deal at Barclays
02/09/21 Barclays
Inphi downgraded to Equal Weight from Overweight at Barclays
GIS General Mills
$61.21 /

-0.29 (-0.47%)

01/19/21 JPMorgan
General Mills price target lowered to $55 from $62 at JPMorgan
01/12/21 Jefferies
General Mills price target lowered to $59 from $64 at Jefferies
09/25/20 Credit Suisse
General Mills upgraded to Outperform from Neutral at Credit Suisse
09/24/20 Citi
General Mills price target lowered to $64 from $70 at Citi
GME GameStop
$181.00 /

-13.41 (-6.90%)

03/24/21 BofA
GameStop Q4 EBITDA missed 'in a big way,' says BofA
03/24/21 Wedbush
Wedbush downgrades GameStop to sell with $29 price target
03/24/21 Wedbush
GameStop downgraded to Underperform from Neutral at Wedbush
03/19/21 BofA
GameStop-related stimulus conversations may not impact shares, says BofA
EYES Second Sight
$11.00 /

-1.65 (-13.04%)

04/01/20 H.C. Wainwright
Second Sight rating placed under review at H.C. Wainwright
MP MP Materials
$37.04 /

-8.165 (-18.06%)

03/10/21 Cowen
MP Materials initiated with an Outperform at Cowen
03/09/21 Deutsche Bank
MP Materials downgraded to Hold on valuation at Deutsche Bank
03/08/21 Deutsche Bank
MP Materials downgraded to Hold from Buy at Deutsche Bank
03/02/21
Fly Intel: Top five analyst initiations
CASI Casi Pharmaceuticals
$2.28 /

-0.11 (-4.60%)

10/23/20 Oppenheimer
Casi Pharmaceuticals initiated with an Outperform at Oppenheimer
BTC Bitcoin
$0.00 /

+ (+0.00%)

01/13/21 Standpoint Research
Bitcoin could hit $112,000 this year, says Standpoint Research
BITCOIN Bitcoin
$0.00 /

+ (+0.00%)

MRVL Marvell
$46.12 /

-1.56 (-3.27%)

03/12/21 Evercore ISI
Marvell added to Top Picks list, price target upped to $55 at Evercore ISI
03/08/21 BMO Capital
Marvell upgraded to Outperform from Market Perform at BMO Capital
03/04/21 Jefferies
Marvell long-term visibility better than previously thought, says Jefferies
TSLA Tesla
$662.17 /

-7.83 (-1.17%)

MRVL Marvell
$46.12 /

-1.56 (-3.27%)

MP MP Materials
$37.04 /

-8.165 (-18.06%)

IPHI Inphi
$161.66 /

-3.58 (-2.17%)

INTC Intel
$63.47 /

-2.19 (-3.34%)

GME GameStop
$181.00 /

-13.41 (-6.90%)

GIS General Mills
$61.21 /

-0.29 (-0.47%)

DLPN Dolphin Entertainment
$18.20 /

+12.78 (+235.79%)

CASI Casi Pharmaceuticals
$2.28 /

-0.11 (-4.60%)

AGRX Agile Therapeutics
$1.89 /

-0.13 (-6.45%)

  • 24
    Mar
  • 24
    Mar
  • 22
    Jul
  • 01
    May
TSLA Tesla
$662.17 /

-7.83 (-1.17%)

IPHI Inphi
$161.66 /

-3.58 (-2.17%)

INTC Intel
$63.47 /

-2.19 (-3.34%)

GME GameStop
$181.00 /

-13.41 (-6.90%)

GIS General Mills
$61.21 /

-0.29 (-0.47%)

BTC Bitcoin
$0.00 /

+ (+0.00%)

TSLA Tesla
$662.17 /

-7.83 (-1.17%)

MRVL Marvell
$46.12 /

-1.56 (-3.27%)

MP MP Materials
$37.04 /

-8.165 (-18.06%)

IPHI Inphi
$161.66 /

-3.58 (-2.17%)

INTC Intel
$63.47 /

-2.19 (-3.34%)

GME GameStop
$181.00 /

-13.41 (-6.90%)

GIS General Mills
$61.21 /

-0.29 (-0.47%)

EYES Second Sight
$11.00 /

-1.65 (-13.04%)

CASI Casi Pharmaceuticals
$2.28 /

-0.11 (-4.60%)

BTC Bitcoin
$0.00 /

+ (+0.00%)

BITCOIN Bitcoin
$0.00 /

+ (+0.00%)

TSLA Tesla
$662.17 /

-7.83 (-1.17%)

MRVL Marvell
$46.12 /

-1.56 (-3.27%)

MP MP Materials
$37.04 /

-8.165 (-18.06%)

INTC Intel
$63.47 /

-2.19 (-3.34%)

GME GameStop
$181.00 /

-13.41 (-6.90%)

GIS General Mills
$61.21 /

-0.29 (-0.47%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.